First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas(Leiden University Medical Center), Arnaud Scherpereel(Inserm), Anna K. Nowak(The University of Western Australia), Nobukazu Fujimoto(Okayama Rosai Hospital), Solange Peters(University Hospital of Lausanne), Anne S. Tsao(The University of Texas MD Anderson Cancer Center), Aaron S. Mansfield(Mayo Clinic), Sanjay Popat(Institute of Cancer Research), Thierry Jahan(UCSF Helen Diller Family Comprehensive Cancer Center), Scott Antonia(Moffitt Cancer Center), Youssef Oulkhouir(Centre Hospitalier Universitaire de Caen Normandie), Yolanda Bautista(Centro Medico Nacional Siglo XXI), Robin Cornelissen(Erasmus MC), Laurent Greillier(Centre National de la Recherche Scientifique), Francesco Grossi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Jerónimo Rafael Rodríguez‐Cid(Instituto Nacional de Enfermedades Respiratorias), Praveen Aanur(Princeton University), Abderrahim Oukessou(Princeton University), Christine Baudelet(Princeton University), Gérard Zalcman(Université Claude Bernard Lyon 1)
Cited by 1,186Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis